Hideho Okada

17.3k total citations · 2 hit papers
198 papers, 8.8k citations indexed

About

Hideho Okada is a scholar working on Immunology, Oncology and Molecular Biology. According to data from OpenAlex, Hideho Okada has authored 198 papers receiving a total of 8.8k indexed citations (citations by other indexed papers that have themselves been cited), including 137 papers in Immunology, 113 papers in Oncology and 58 papers in Molecular Biology. Recurrent topics in Hideho Okada's work include Immunotherapy and Immune Responses (101 papers), CAR-T cell therapy research (74 papers) and Glioma Diagnosis and Treatment (55 papers). Hideho Okada is often cited by papers focused on Immunotherapy and Immune Responses (101 papers), CAR-T cell therapy research (74 papers) and Glioma Diagnosis and Treatment (55 papers). Hideho Okada collaborates with scholars based in United States, Japan and Switzerland. Hideho Okada's co-authors include Gary Kohanbash, Ian F. Pollack, Mitsugu Fujita, Ronald L. Hamilton, Xinmei Zhu, Walter J. Storkus, Ryo Ueda, Theresa L. Whiteside, William H. Chambers and Michael T. Lotze and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Investigation and Nature Communications.

In The Last Decade

Hideho Okada

194 papers receiving 8.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Immunotherapy response assessment in neuro-oncology: a report of the RANO working group

2015 471 citations Hideho Okada, Ian F. Pollack et al. profile →
Single-cell profiling of human gliomas reveals macrophage ontogeny as a basis for regional differences in macrophage activation in the tumor microenvironment

2017 434 citations Sören Müller, Gary Kohanbash et al. profile →

Peers

Countries citing papers authored by Hideho Okada

Since Specialization

Citations

This map shows the geographic impact of Hideho Okada's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hideho Okada with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hideho Okada more than expected).

Fields of papers citing papers by Hideho Okada

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hideho Okada. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hideho Okada. The network helps show where Hideho Okada may publish in the future.

Co-authorship network of co-authors of Hideho Okada

This figure shows the co-authorship network connecting the top 25 collaborators of Hideho Okada. A scholar is included among the top collaborators of Hideho Okada based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hideho Okada. Hideho Okada is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Ultrasound frequency-controlled microbubble dynamics in brain vessels regulate the enrichment of inflammatory pathways in the blood-brain barrier 2024 ·Nature Communications ·Yutong Guo, (unknown), (unknown), C.-S. Park, Akane Yamamichi, Pavlina Chuntova, Marco Gallus, Miguel O. Bernabéu, Hideho Okada, Hanjoong Jo, Costas Arvanitis	18
2	Activating the dark genome to illuminate cancer vaccine targets 2024 ·Nature Genetics ·(unknown), Hideho Okada, J Costello	2
3	DIPG-15. NOVEL CNS SENSING SYNNOTCH-CAR T CELLS FOR TARGETING DIFFUSE MIDLINE GLIOMA 2024 ·Neuro-Oncology ·(unknown), Milos Simic, (unknown), Payal Watchmaker, Haoyu Long, (unknown), (unknown), (unknown), Wei Yu, (unknown), (unknown), Olga G. Troyanskaya, Lia Cardarelli, Sachdev S. Sidhu, Wendell A. Lim, Hideho Okada	1
4	IL-13Rα2/TGF-β bispecific CAR-T cells counter TGF-β-mediated immune suppression and potentiate anti-tumor responses in glioblastoma 2024 ·Neuro-Oncology ·Andrew J. Hou, (unknown), Benjamin R. Uy, (unknown), (unknown), Begonya Comin-Anduix, (unknown), Zoran Galić, Su Phyu, Hideho Okada, (unknown), Joshua J. Breunig, Christine E. Brown, David A. Nathanson, Robert M. Prins, Yvonne Y. Chen	32
5	Quantitative analysis of MGMT promoter methylation in glioblastoma suggests nonlinear prognostic effect 2023 ·Neuro-Oncology Advances ·David R. Gibson, (unknown), Eduardo A. Rodríguez, Susan M. Chang, (unknown), Jennie Taylor, Jennifer Clarke, David A. Solomon, (unknown), John S. Witte, (unknown), Hideho Okada, Mitchel S. Berger, Farid Chehab, Nicholas Butowski	6
6	Immunotherapy Approaches in Isocitrate-Dehydrogenase-Mutant Low-Grade Glioma 2023 ·Cancers ·Marco Gallus, (unknown), (unknown), Akane Yamamichi, Hideho Okada	11
7	Novel EGFRvIII-CAR transgenic mice for rigorous preclinical studies in syngeneic mice 2021 ·Neuro-Oncology ·Pavlina Chuntova, Yafei Hou, (unknown), Akane Yamamichi, Tiffany Chen, Yitzhar Goretsky, Ryusuke Hatae, Takahide Nejo, Gary Kohanbash, (unknown), (unknown), Kira Downey, (unknown), (unknown), Hong-Erh Liang, Bjoern Schwer, Hideho Okada	11
8	The Great Debate at ‘Immunotherapy Bridge’, Naples, December 5, 2019 2020 ·Journal for ImmunoTherapy of Cancer ·Paolo A. Ascierto, Carlo Bifulco, (unknown), Claus Garbe, Samir N. Khleif, Jennifer L. McQuade, Kunle Odunsi, Hideho Okada, Chrystal M. Paulos, Sergio A. Quezada, Hussein A. Tawbi, John M. Timmerman, Giorgio Trinchieri, Lisa H. Butterfield, Igor Puzanov	2
9	Peptide vaccine immunotherapy biomarkers and response patterns in pediatric gliomas 2018 ·JCI Insight ·Sören Müller, Sameer Agnihotri, (unknown), (unknown), (unknown), Srilakshmi Chaparala, (unknown), Ansuman Chattopadhyay, Adrian V. Lee, Lisa H. Butterfield, Aarón Díaz, Hideho Okada, Ian F. Pollack, Gary Kohanbash	24
10	Induction of Robust Type-I CD8+ T-cell Responses in WHO Grade 2 Low-Grade Glioma Patients Receiving Peptide-Based Vaccines in Combination with Poly-ICLC 2014 ·Clinical Cancer Research ·Hideho Okada, Lisa H. Butterfield, Ronald L. Hamilton, Aki Hoji, Masashi Sakaki, Brian Ahn, Gary Kohanbash, Jan Drappatz, Johnathan A. Engh, Nduka Amankulor, Mark O. Lively, Michael D. Chan, Andres Μ. Salazar, Edward G. Shaw, Douglas M. Potter, Frank S. Lieberman	83
11	STING Contributes to Antiglioma Immunity via Triggering Type I IFN Signals in the Tumor Microenvironment 2014 ·Cancer Immunology Research ·Takayuki Ohkuri, Arundhati Ghosh, Akemi Kosaka, Jianzhong Zhu, Maki Ikeura, Michael David, Simon C. Watkins, Saumendra N. Sarkar, Hideho Okada	196
12	GM-CSF Promotes the Immunosuppressive Activity of Glioma-Infiltrating Myeloid Cells through Interleukin-4 Receptor-α 2013 ·Cancer Research ·Gary Kohanbash, (unknown), Masashi Sakaki, Ryo Ueda, Arlan Mintz, Nduka Amankulor, Mitsugu Fujita, John R. Ohlfest, Hideho Okada	134
13	LOH in the HLA Class I Region at 6p21 Is Associated with Shorter Survival in Newly Diagnosed Adult Glioblastoma 2013 ·Clinical Cancer Research ·Jacky T. Yeung, Ronald L. Hamilton, Koji Ohnishi, Maki Ikeura, Douglas M. Potter, Marina N. Nikiforova, Soldano Ferrone, Regina I. Jakacki, Ian F. Pollack, Hideho Okada	71
14	COX-2 Blockade Suppresses Gliomagenesis by Inhibiting Myeloid-Derived Suppressor Cells 2011 ·Cancer Research ·Mitsugu Fujita, Gary Kohanbash, Wendy Fellows-Mayle, Ronald L. Hamilton, Yoshihiro Komohara, Stacy A. Decker, John R. Ohlfest, Hideho Okada	315
15	Role of Type 1 IFNs in Antiglioma Immunosurveillance—Using Mouse Studies to Guide Examination of Novel Prognostic Markers in Humans 2010 ·Clinical Cancer Research ·Mitsugu Fujita, Michael E. Scheurer, Stacy A. Decker, Heather A. McDonald, Gary Kohanbash, Edward R. Kastenhuber, Hisashi Kato, Melissa L. Bondy, John R. Ohlfest, Hideho Okada	76
16	Systemic Inhibition of Transforming Growth Factor-β in Glioma-Bearing Mice Improves the Therapeutic Efficacy of Glioma-Associated Antigen Peptide Vaccines 2009 ·Clinical Cancer Research ·Ryo Ueda, Mitsugu Fujita, Xinmei Zhu, Kotaro Sasaki, Edward R. Kastenhuber, Gary Kohanbash, Heather A. McDonald, Jay Harper, Scott Lonning, Hideho Okada	94
17	Effective Immunotherapy against Murine Gliomas Using Type 1 Polarizing Dendritic Cells—Significant Roles of CXCL10 2009 ·Cancer Research ·Mitsugu Fujita, Xinmei Zhu, Ryo Ueda, Kotaro Sasaki, Gary Kohanbash, Edward R. Kastenhuber, Heather A. McDonald, Gregory A. Gibson, Simon C. Watkins, Ravikumar Muthuswamy, Paweł Kaliński, Hideho Okada	84
18	Dicer-regulated micro RNAs 222 and 339 promote immune-escape of cancer cells through downregulation of ICAM-1 2008 ·Cancer Research ·Ryo Ueda, Gary Kohanbash, Kotaro Sasaki, Mitsugu Fujita, Xinmei Zhu, Michael T. Lotze, Robert W. Sobol, Hideho Okada	1
19	Preferential Expression of Very Late Antigen-4 on Type 1 CTL Cells Plays a Critical Role in Trafficking into Central Nervous System Tumors 2007 ·Cancer Research ·Kotaro Sasaki, Xinmei Zhu, (unknown), Fumihiko Nishimura, Jill E. Dusak, Jian Huang, Mitsugu Fujita, Amy Wesa, Douglas M. Potter, Paul R. Walker, Walter J. Storkus, Hideho Okada	49
20	Adoptive Transfer of Type 1 CTL Mediates Effective Anti–Central Nervous System Tumor Response: Critical Roles of IFN-Inducible Protein-10 2006 ·Cancer Research ·Fumihiko Nishimura, Jill E. Dusak, Junichi Eguchi, Xinmei Zhu, Andrea Gambotto, Walter J. Storkus, Hideho Okada	73

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact